BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21372602)

  • 1. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
    Ishigami H; Kitayama J; Kaisaki S; Yamaguchi H; Yamashita H; Emoto S; Nagawa H
    Oncology; 2010; 79(3-4):269-72. PubMed ID: 21372602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer.
    Ishigami H; Kitayama J; Otani K; Kamei T; Soma D; Miyato H; Yamashita H; Hidemura A; Kaisaki S; Nagawa H
    Oncology; 2009; 76(5):311-4. PubMed ID: 19299904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
    Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Three advanced gastric cancer patients successfully treated by combination therapy of paclitaxel and cisplatin].
    Yamada T; Tanaka N; Yokoi K; Ishikawa N; Seya T; Horiba K; Kanazawa Y; Shirakawa T; Ohkawa K; Kudoh H; Koizumi M; Yoshioka M; Shinji S; Katsuta M; Yamashita K; Tajiri T
    Gan To Kagaku Ryoho; 2007 May; 34(5):769-72. PubMed ID: 17496455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.
    Park SR; Oh DY; Kim DW; Kim TY; Heo DS; Bang YJ; Kim NK; Kang WK; Kim HT; Im SA; Suh JH; Kim HK; Kim HK
    Oncol Rep; 2004 Nov; 12(5):1059-64. PubMed ID: 15492793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
    Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial.
    Kodera Y; Takahashi N; Yoshikawa T; Takiguchi N; Fujitani K; Ito Y; Miyamoto K; Takayama O; Imano M; Kobayashi D; Miyashita Y; Morita S; Sakamoto J
    Gastric Cancer; 2017 Jan; 20(1):190-199. PubMed ID: 26879545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
    Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
    Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
    Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
    Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of paclitaxel and cisplatin for patients with advanced or recurrent gastric cancer.
    Nagata N; Kobayashi M; Kojima H; Kondo K; Hirabayashi N; Matsui T; Kataoka M; Takiyama W; Miyashita Y; Nakazato H; Araki K; Itoh H; Nakao A; Sakamoto J
    Hepatogastroenterology; 2005; 52(66):1905-10. PubMed ID: 16334804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The updated treatment strategy for gastric cancer with peritoneal metastasis].
    Ishigami H; Kaisaki S; Kitayama J
    Nihon Geka Gakkai Zasshi; 2012 Jan; 113(1):18-21. PubMed ID: 22413551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
    Kim JY; Do YR; Park KU; Kim JG; Chae YS; Kim MK; Lee KH; Ryoo HM; Bae SH; Baek JH; Song HS
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):527-32. PubMed ID: 20461377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma.
    Yoshikawa T; Tsuburaya A; Hirabayashi N; Yoshida K; Nagata N; Kodera Y; Takahashi N; Oba K; Kimura M; Ishikura S; Miyashita Y; Sakamoto J
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1071-7. PubMed ID: 19283353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
    Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
    Anticancer Res; 2018 Oct; 38(10):5969-5974. PubMed ID: 30275227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
    Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T
    Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
    Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
    Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An effective treatment by chemotherapy with S-1 and CDDP intraperitoneal administration for the peritoneal dissemination of gastric cancer--a case report].
    Kadono M; Iwasaki Y; Ohashi M; Iwanaga T; Ohinata R; Takahashi K; Yamaguchi T; Matsumoto H; Nakano D
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2442-4. PubMed ID: 21224600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.